Treatment could spur production of insulin in Type 1 diabetes
GAINESVILLE, Fla. — Combining two different medications could help patients with Type 1 diabetes at least partially regain the ability to produce their own insulin, a University of Florida study has shown.
Dr. Michael Haller, a pediatric endocrinologist, likens his approach to treating Type 1 diabetes to a game of cops and robbers. First, he ferrets out problematic cells of the immune system that could be behind a patient’s inability to produce insulin and wipes them out with a medication called Thymoglobulin, a drug initially developed for use in organ transplantation. Then he uses a medication called Neulasta, a drug designed to improve the lives of people with certain forms of cancer, to stimulate the production of new and potentially beneficial immune cells. Haller presented the results of the study on Sunday at the annual meeting of the American Diabetes Association in San Francisco.
“The treatment is almost like trying to hit the reset button on the immune system,” Haller said. “We’re trying to wipe out the bad cells and stimulate the good cells at the same time.”
Haller treated 17 adult Type 1 diabetes patients for two weeks with the cocktail therapy and then followed them for a year. Another eight patients were given a placebo. By the end of the year, the patients treated with the cocktail had increased their ability to produce insulin. This indicates that the Thymoglobulin was successful in killing the bad immune system cells, and the Neulasta was successful in stimulating new, healthy immune cells. The researchers also say the patients’ ability to produce insulin indicates they had an increase in beta cells, the cells responsible for producing insulin in the pancreas.
According to conventional diabetes wisdom, within just a few months of the onset of Type 1 diabetes, there are very few of the insulin-producing beta cells left in the pancreas, said Mark Atkinson, a co-investigator in this study and member of the department of pathology, immunology and laboratory medicine. That the treatment seemed to stimulate insulin production in people with established Type 1 diabetes made the researchers “cautiously optimistic,” Atkinson said.
“The results that Dr. Haller saw in his first study are profound,” Atkinson said.
The study was also novel in that it worked with patients who had been long diagnosed with the disease. Typically, studies examine patients who are newly diagnosed and still have a reasonable number of beta cells producing insulin. The patients in Haller’s study had been living with Type 1 diabetes between four months and two years.
“The model has mostly been to test therapies aimed at beta cell preservation in people who have just been diagnosed,” Haller said. “But obviously, the majority of patients living with the disease have been living with the disease for a long time, so people become disenfranchised from the research process. We’re interested in making life better for these patients.”
Atkinson began considering Thymoglobulin as a treatment for diabetes nearly a decade ago. He and fellow co-investigator Dr. Desmond Schatz, associate chairman of the department of pediatrics, authored a paper advocating a combination approach to treating Type 1 diabetes. Based on Schatz’s belief in so-called combination therapies, the group began shepherding a cocktail of Thymoglobulin and Neulasta through early studies done with mouse models.
“Despite tremendous strides in our understanding of the natural history of Type 1 diabetes, we are as yet unable to cure and prevent the disease,” Schatz said. “This study is a step in that direction, toward a biological cure.”
The patients in Haller’s study will be followed for three to five years to see if their bodies will preserve the insulin-producing beta cells. The researchers’ next step will be to recruit patients who have been newly diagnosed with the disease to conduct a larger trial.
Haller says he hopes the approach will help patients manage their disease more easily.
“If we can confirm the results in a larger effort, the study could potentially be paradigm-shifting for our field in that it documents we should really be looking at combination therapies in treating Type 1 diabetes,” Haller said. “Our ultimate goal is to prevent and cure this disease, but we have to crawl before we walk, and walk before we run. This study is an important step forward in our efforts to make life easier for patients with Type 1 diabetes.”
The Helmsley Charitable Trust funded the study.